Genetic test indications and interpretations in patients with hereditary angioedema

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 958-972

  Weiler, Catherine R ^a   Van Dellen, Richard G ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; FRESH FROZEN PLASMA; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; PROTEINASE INHIBITOR; STANOZOLOL;

ANDROGEN THERAPY; ANGIONEUROTIC EDEMA; ANTIGENICITY; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; ENDOTHELIUM CELL; FAMILY HISTORY; FAMILY PLANNING; GENE MUTATION; GENETIC ANALYSIS; GENETIC COMPLEMENTATION; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; PATHOPHYSIOLOGY; RECURRENT DISEASE; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT INDICATION;

EID: 33745633580     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.958     Document Type: Article

References (251)

1. Rosen FS, Davis AE III. Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol. 2005;19:251-261.
2. Rosen FS, Austen KF. The "neurotic edema" (hereditary angioedema). N Engl J Med. 1969;280:1356-1357.
3. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114:10-16.
4. Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29:239-245.
5. Binkley KE, Davis AE III. Estrogen-dependent inherited angioedema. Transfus Apher Sci. 2003;29:215-219.
6. Binkley KE, Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546-550.
7. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595-628.
8. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(suppl):S51-131.
9. McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci. 2000;320:212-213.
10. Warin RP, Cunliffe WJ, Greaves MW, Wallington TB. Recurrent angioedema: familial and oestrogen-induced. Br J Dermatol. 1986;115:731-734.
11. Arreaza EE, Singh K, Grant JA. Hereditary angioedema: clinical and biochemical heterogeneity. Ann Allergy. 1988;61:69-74.
12. Davis AE III. Hereditary and acquired deficiencies of C1 inhibitor. Immunodefic Rev. 1989;1:207-226.
13. Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin North Am. 1985;69:487-504.
14. Oltvai ZN, Wong EC, Atkinson JP, Tung KS. C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. Lab Invest. 1991;65:381-388.
15. Kaplan AP. C1 inhibitor deficiency: hereditary and acquired forms. J Investis Allergol Clin Immunol. 2001;11:211-219.
16. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria- angioedema. J Allergy Clin Immunol. 2000;105:997-1001.
17. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387-391.
18. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med. 1999;106:650-654.
19. Hill JS. Urticaria and angioedema: common clinical problems. Postgrad Med. 1979;65:83-86, 89-90.
20. Roberts JR, Wuerz RC. Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med. 1991;20:555-558.
21. Orfan N, Patterson R, Dykewicz MS. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA. 1990;264:1287-1289.
22. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest. 2004;126:400-404.
23. Fuchs SA, Meyboom RH, van Puijenbroek EP, Guchelaar HJ. Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. Pharm World Sci. 2004;26:191-192.
24. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol. 2004;4:267-270.
25. Bork K, Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med. 2004;116:644-645.
26. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope. 2001;111:1729-1731.
27. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114:629-637.
28. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52:91-112.
29. Dickneite G. Influence of C1-inhibitor on inflammation, edema and shock. Behring Inst Mitt. 1993;93:299-305.
30. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin II and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med. 1999;27:597-604.
31. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
32. Nurnberger W, Heying R, Burdach S, Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol. 1997;75:95-101.
33. Scherer M, Demertzis S, Langer F, Moritz A, Schafers HJ. C1-esterase inhibitor reduces reperfusion injury after lung transplantation. Ann Thorac Surg. 2002;73:233-238.
34. Matsunami K, Miyagawa S, Yamada M, Nakai R, Yoshitatsu M, Shirakura R. A surface-bound form of human C1 esterase inhibitor on xenografts: the complement regulatory function. Transplant Proc. 2000;32:901-902.
35. Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int. 2000;13(suppl 1):S547-S550.
36. Wong DT, Gadsden JC. Acute upper airway angioedema secondary to acquired C1 esterase inhibitor deficiency: a case report. Can J Anaesth. 2003;50:900-903.
37. Sofia S, Casali A, Bolondi L. Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound. 1999;27:537-540.
38. Shah TJ, Knowles WO, McGeady SJ. Hereditary angioedema with recurrent abdominal pain and ascites. J Allergy Clin Immunol. 1995;96:259-261.
39. Wilson CL. Hereditary angioedema: a potential clinical emergency. CRNA. 1996;7:108-109.
40. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci. 2003;29:235-238.
41. Sunder TR, Balsam MJ, Vengrow MI. Neurological manifestations of angioedema: report of two cases and review of the literature. JAMA. 1982;247:2005-2007.
42. Neri S, Ierna D, Sfogliano L. Unusual manifestations of hereditary angioedema. Eur J Emerg Med. 2000;7:111-112.
43. Van Dellen RG, Myers RP. Bladder involvement in hereditary angioedema. Mayo Clin Proc. 1980;55:277-278.
44. Donaldson VH. C1-inhibitor in hereditary angioneurotic edema: types I and II. Behring Inst Mitt. 1989;84:151-160.
45. Gupta S, Yu F, Klaustermeyer WB. New-variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function. Allergy. 2004;59:557-558.
46. Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976;48:567-580.
47. Cicardi M, Beretta A, Colombo M, Gioffre D, Cugno M, Agostoni A. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol. 1996;106:475-480.
48. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore). 2003;82:274-281.
49. Gaur S, Cooley J, Aish L, Weinstein R. Lymphoma-associated paraneoplastic angioedema with normal C1-inhibitor activity: does danazol work? Am J Hematol. 2004;77:296-298.
50. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med. 1985;312:534-540.
51. Jackson J, Sim RB, Whelan A, Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986;323:722-724.
52. Alsenz J, Lambris JD, Bork K, Loos M. Acquired C1 inhibitor (C1-INH) deficiency type II: replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest. 1989;83:1794-1799.
53. Valsecchi R, Reseghetti A, Pansera B, Di Landro A. Autoimmune C1 inhibitor deficiency and angioedema. Dermatology. 1997;195:169-172.
54. He S, Sim RB, Whaley K. Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes. MoL Med. 1998;4:119-128.
55. Donaldson VH, Rosen FS, Bing DH. Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. Adv Exp Med Biol. 1983;156:183-191.
56. Kellermeyer RW, Graham RC Jr. Kinins: possible physiologic and pathologic roles in man. N Engl J Med. 1968;279:859-866.
57. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
58. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104:1321-1322.
59. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-1063.
60. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.
61. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109:195-209.
62. Curd JG, Prograis LJ Jr, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med. 1980;152:742-747.
63. Ratnoff OD, Pensky J, Ogston D, Naff GB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C′1r subcomponent of the first component of complement by serum C′1 esterase inhibitor. J Exp Med. 1969;129:315-331.
64. Austen KF. Inborn and acquired abnormalities of the complement system of man. Johns Hopkins Med J. 1971;128:57-74.
65. Kaplan AP, Ghebrehiwet B, Silverberg M, Sealey JE. The intrinsic coagulation-kinin pathway, complement cascades, plasma rennin-angiotensin system, and their interrelationships. Crit Rev Immunol. 1981;3:75-93.
66. Cullmann W, Kovary PM, Muller N, Dick W. Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin Exp Immunol. 1982;49:618-622.
67. Donaldson VH, Harrison RA. Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation. Blood. 1982;60:121-129.
68. Davis AE III. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003;29:195-203.
69. Davis AE III. Biological effects of C1 inhibitor. Drug News Perspect. 2004;17:439-446.
70. James K. Complement: activation, consequences, and control. Am J Med Technol. 1982;48:735-742.
71. Ziccardi RJ. The first component of human complement (C1): activation and control. Springer Semin Immunopathol. 1983;6:213-230.
72. Lim HW. The complement system: activation, modulation, and clinical relevance. Dermatol Clin. 1990;8:609-618.
73. Meri S, Jarva H. Complement regulation. Vox Sang. 1998;74(suppl 2):291-302.
74. Fust G, Medgyesi GA, Rajnavolgyi E, Csecsi-Nagy M, Czikora K, Gergely J. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1. Immunology. 1978;35:873-884.
75. Kaplan AP. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation. Fed Proc. 1983;42:3123-3127.
76. Proud D, Kaplan AP. Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol. 1988;6:49-83.
77. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987;70:1-15.
78. Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Hemost. 1987;13:1-14.
79. Colman RW, Girey GJ, Zacest R, Talamo RC. The human plasma kallikrein-kinin system. Prog Hematol. 1971;7:255-298.
80. Schapira M, Scott CF, Colman RW. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors: the role of high molecular weight kininogen. Biochemistry. 1981;20:2738-2743.
81. Schapira M, Scott CF, James A, et al. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry. 1982;21:567-572.
82. Kaplan AP. Mechanisms of bradykinin generation in human plasma. Monogr Allergy. 1983;18:272-276.
83. Colman RW, Mason JW, Sherry S. The kallikreinogen-kallikrein enzyme system of human plasma: assay of components and observations in disease states. Ann Intern Med. 1969;71:763-773.
84. Purdon AD, Schapira M, De Agostini A, Colman RW. Plasma kallikrein and prorenin in patients with hereditary angioedema. J Lab Clin Med. 1985;105:694-699.
85. --inhibitor. Biol Chem Hoppe Seyler. 1987;368:1203-1213.
86. Roberts ML, Mashford ML. Possible physiological and pathological roles of the kallikrein-kinin system. Med J Aust. 1972;2:887-891.
87. Colman RW. Formation of human plasma kinin. N Engl J Med. 1974;291:509-515.
88. Donaldson VH. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int Arch Allergy Appl lmmunol. 1973;45:206-209.
89. Witzke G, Bork K, Benes P, Bockers M. Hereditary angioneurotic oedema and blood-coagulation: interaction between C1-esterase-inhibitor and the activation factors of the proteolytic enzyme systems. Klin Wochenschr. 1983;61:1131-1135.
90. Bleumink E, Doeglas HM. Protease inhibitor deficiencies in patients with angio-oedema. Clin Exp Dermatol. 1986;11:274-283.
91. Davis AE III. Structure and function of C1 inhibitor. Behring Inst Mitt. 1989;84:142-150.
92. Perkins SJ. Three-dimensional structure and molecular modelling of C1-inhibitor. Behring Inst Mitt. 1993;93:63-80.
93. Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol. 1970;104:574-581.
94. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993;121:38-43.
95. Donaldson VH. Plasminogen activation in hereditary angioneurotic edema. J Lab Clin Med. 1993;121:13-14.
96. Francis CW, Brenner B, Leddy JP, Marder VJ. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol. 1991;77:562-563.
97. Rudolf J, Grond M, Schmulling S, Neveling M, Heiss W. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. 2000;55:599-600.
98. Brown EW, Ravindran S, Patston PA. The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coagul Fibrinolysis. 2002;13:711-714.
99. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke. 2002;33:1712-1716.
100. Prograis LJ Jr, Brickman CM, Frank MM. Protease inhibitors of human plasma: C1-inhibitor (C1-INH). J Med. 1985;16:303-350.
101. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma: predominant role of C-1-inhibitor. J Clin Invest. 1984;73:1542-1549.
102. Weiss R, Silverberg M, Kaplan AP. The effect of C1 inhibitor upon Hageman factor autoactivation. Blood. 1986;68:239-243.
103. Ratnoff OD. Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments. Blood. 1981;57:55-58.
104. Kaplan AP, Gruber B, Harpel PC. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood. 1985;66:636-641.
105. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
106. Highsmith RF, Burnett CJ, Weirich CJ. The interaction of C1-esterase inhibitor and plasmin in human euglobulin. J Lab Clin Med. 1979;93:459-471.
107. van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest. 1983;71:149-158.
108. Lewin MF, Kaplan AP, Harpel PC. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. J Biol Chem. 1983;258:6415-6421.
109. --inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol. 1984;82:396-404.
110. Chan JY, Burrowes CE, Habal FM, Movat HZ. The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. Biochem Biophys Res Commun. 1977;74:150-158.
111. Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry. 1993;32:12136-12147.
112. Schapira M, James A, Scott CF, et al. Role of high molecular weight kininogen in modulating the inactivation of human plasma kallikrein by plasma protease inhibitors. Adv Exp Med Biol. 1983;156:131-141.
113. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982;69:462-468.
114. Scott CF, Carrell RW, Glaser CB, Kueppers F, Lewis JH, Colman RW. Alpha-1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest. 1986;77:631-634.
115. 358 → Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. J Clin Invest. 1985;76:635-637.
116. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69:209-216.
117. Haselager EM, Goote TM, Vreeken J. Plasmin inactivation in plasma. Thromb Haemost. 1976;35:643-650.
118. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977;484:417-422.
119. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342-345.
120. Ritchie BC. Protease inhibitors in the treatment of hereditary angioedema. Transfus Apher Sci. 2003;29:259-267.
121. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236-261.
122. McNicol GP, Douglas AS. Epsilon-aminocaproic acid and other inhibitors of fibrinolysis. Br Med Bull. 1964;20:233-239.
123. Verstraete M. Future prospects for use of fibrinolysis inhibitors. J Clin Pathol Suppl (R Coll Pathol). 1980;14:77-80.
124. Laurberg G. Plasma kinin activation in tranexamic acid treated patients with hereditary angioneurotic edema. Arch Dermatol Res. 1978;262:153-156.
125. Spragg J. Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects. J Immunol. 1978;120:592-596.
126. Miles LA, Burnier JP, Verlander MS, Goodman M, Kleiss AJ, Griffin JH. Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents. Blood. 1981;57:1015-1024.
127. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med. 1972;286:808-812.
128. Pence HL, Evans R, Guernsey LH, Gerhard RC. Prophylactic use of epsilon aminocaproic acid for oral surgery in a patient with hereditary angioneurotic edema. J Allergy Clin Immunol. 1974;53:298-302.
129. Fernandez M, Dieguez I, Neffen H, Oehling A. Epsilon-amino-caproic acid in the treatment of Osler's hereditary angioneurotic edema. Allergol Immunopathol (Madr). 1983;11:19-23.
130. Carugati A, Pappalardo E, Zingale LC, Cicardi M. C1-inhibitor deficiency and angioedema. Mol Immunol. 2001;38:161-173.
131. Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett. 2003;86:271-276.
132. Gluszko P, Undas A, Amenta S, Szczeklik A, Schmaier AH. Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. J Lab Clin Med. 1994;123:232-240.
133. Mathews KP, Pan PM, Gardner NJ, Hugli TE. Familial carboxypeptidase N deficiency. Ann Intern Med. 1980;93:443-445.
134. Sigler C, Annis K, Cooper K, Haber H, Van deCarr S. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol. 1997;133:972-975.
135. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088-2089.
136. Blais C Jr, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology. 1999;43:293-302.
137. 9-bradykinin. J Pharmacol Exp Ther. 2002;303:232-237.
138. Sunman W, Sever PS. Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clin Sci (Lond). 1993;85:661-670.
139. Sreeram AB, Corey JP. Congenital angiotensin-converting enzyme deficiency presenting as recurrent angioedema of upper airway in adult life. Otolaryngol Head Neck Surg. 1995;112:421-423.
140. Fuller RW, Warren JB, McCusker M, Dollery CT. Effect of enalapril on the skin response to bradykinin in man. Br J Clin Pharmacol. 1987;23:88-90.
141. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164:910-913.
142. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229-1235.
143. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980;302:542-546.
144. Phillips M. C1-inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 1980;303:526-527.
145. Maves KK, Weiler JM. Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. Ann Allergy. 1994;73:435-438.
146. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:1630-1634.
147. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating heredi-tary angioedema. Transfusion. 1998;38:540-549.
148. Rosen FS, Austen KF. Androgen therapy in hereditary angioneurotic edema. N Engl J Med. 1976;295:1476-1477.
149. Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol. 1980;65:75-79.
150. Rosen FS, Beyler A. Hereditary angioneurotic edema and its correction with androgen therapy. Birth Defects Orig Artic Ser. 1980;16:499-507.
151. Danazol and other androgens for hereditary angioedema. Med Lett Drugs Ther. 1981;23:83-84.
152. Scheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981;68:181-187.
153. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991;87:768-773.
154. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol. 1997;99:194-196.
155. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci. 2003;29:221-227.
156. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid: a random double-blind cross-over study. Acta Med Scand. 1972;192:293-298.
157. Scheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287:452-454.
158. Scheffer AL, Fearon DT, Austen KF, Rosen FS. Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema. J Allergy Clin Immunol. 1977;60:38-40.
159. Birgerson L. Tranexamic acid in the treatment of hereditary angioedema. Am J Med. 1991;91:102.
160. Van Dellen RG. Long-term treatment of C1 inhibitor deficiency with epsilon-aminocaproic acid in two patients. Mayo Clin Proc. 1996;71:1175-1178.
161. Jaffe CJ, Atkinson JP, Gelfand JA, Frank MM. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol. 1975;55:386-393.
162. Roth M, Schreier L, Cutler R. Adrenalin treatment for hereditary angioneurotic edema. Ann Allergy. 1975;35:175-179.
163. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol. 1991;25:155-161.
164. Huston DP, Bressler RB. Urticaria and angioedema. Med Clin North Am. 1992;76:805-840.
165. Wood SM, Mann RD, Rawlins MD. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1987;294:91-92.
166. Bielory L, Lee SS, Holland CL, Jaker M. Long-acting ACE inhibitor-induced angioedema. Allergy Proc. 1992;13:85-87.
167. Jason DR. Fatal angioedema associated with captopril. J Forensic Sci. 1992;37:1418-1421.
168. Fine RM. The Fine page: angiotensin converting enzyme angioedema. Int J Dermatol. 1993;32:95-96.
169. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
170. Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med. 1996;26:777-782.
171. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J. 1997;90:552-553.
172. Peled M, Ardekian L, Schnarch A, Laufer D. Preoperative prophylaxis for C1 esterase-inhibitor deficiency in patients undergoing oral surgery: a report of three cases. Quintessence Int. 1997;28:169-171.
173. Maeda S, Miyawaki T, Nomura S, Yagi T, Shimada M. Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:540-543.
174. Bork K, Barnstedt SE. Treatment of 193 episodes of layngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161:714-718.
175. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29:247-254.
176. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol. 1989;83:677-682.
177. Calvert GD, Kilpatrick D, McQueen EG, Houston IB, Kilpatrick JA, Veale AM. Hereditary angioneurotic oedema. N Z Med J. 1973;78:337-342.
178. Owen RM. Treatment of familial angio-oedema. Lancet. 1969;1:574.
179. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23:1355-1390.
180. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet. 1999;353:1066-1067.
181. Chen RH, Frazier OH, Cooley DA. Antifibrinolytic therapy in cardiac surgery. Tex Heart Inst J. 1995;22:211-215.
182. Roos YBWEM, Kinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2003;2:CD001245.
183. Hamilton AG, Bosley AR, Bowen DJ. Laryngeal oedema due to hereditary angioedema. Anaesthesia. 1977;32:265-267.
184. Brodkin HM. Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy: case report. J Neurosurg. 1980;53:690-692.
185. Vanneste JA, van Wijngaarden GK. Epsilon-aminocaproic acid myopathy: report of a case and literature review. Eur Neurol. 1982;21:242-248.
186. Pitts TO, Spero JA, Bontempo FA, Greenberg A. Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. Am J Kidney Dis. 1986;8:441-444.
187. Connelly NR, Kiessling BM, Brull SJ. Does tranexamic acid decrease bleeding in patients undergoing cardiopulmonary bypass? Yale J Biol Med. 1994;67:265-268.
188. Martin-Hirsch PL, Kitchener H. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2000;2:CD001421.
189. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother. 2001;35:925-934.
190. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63:1417-1433.
191. White A, O'Reilly BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol Allied Sci. 1988;13:11-16.
192. Munch EP, Weeke B. Non-hereditary angioedema treated with tranexamic acid: a 6-month placebo controlled trial with follow-up 4 years later. Allergy. 1985;40:92-97.
193. Davies D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet. 1977;1:49.
194. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci. 2003;29:255-258.
195. Tanaka KA, Szlam F, Katori N, Vega JD, Levy JH. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res. 2004;113:333-339.
196. Smith MA, Kerr MA. Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency. Immunology. 1985;56:561-570.
197. Gama Landgraf R, Jancar S, Steil AA, Sirois P. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm Res. 2004 Feb;53:78-83. Epub 2004 Jan 26.
198. Lapointe N, Rouleau JL. Cardioprotective effects of vasopeptidase inhibitors. Can J Cardiol. 2002;18:415-420.
199. Hogan MB, Harris KE, Protter AA, Patterson R. A bradykinin antagonist inhibits both bradykinin- and the allergen-induced airway response in primates. Proc Assoc Am Physicians. 1997;109:269-274.
200. Trifilieff A, Amrani Y, Landry Y, Gies JP. Comparative action of new highly potent bradykinin receptor antagonists in the guinea-pig trachea. Eur J Pharmacol. 1993;239:227-229.
201. Proud D, Reynolds CJ, Broomfield J, Goldman DW, Bathon JM. Bradykinin effects in guinea pig tracheal epithelial cells are mediated through a B2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. J Pharmacol Exp Ther. 1993;264:1124-1131.
202. Sakamoto T, Elwood W, Barnes PJ, Chung KF. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. Eur J Pharmacol. 1992;213:367-373.
203. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes
204. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
205. Gorlach C, Hortobagyi T, Hortobagyi S, et al. Bradykinin B2, but not B1, receptor antagonism has a neuroprotective effect after brain injury. J Neurotrauma. 2001;18:833-838.
206. Kindgen-Milles D, Klement W. Pain and inflammation evoked in human skin by bradykinin receptor antagonists. Eur J Pharmacol. 1992;218:183-185.
207. Sharma JN, Al-Dhalmawi GS. Bradykinin receptor antagonists: therapeutic implications. IDrugs. 2003;6:581-586.
208. Icatibant: HOE 140, JE 049, JE049. Drugs R D. 2004;5:343-348.
209. Sawutz DG, Salvino JM, Dolle RE, Seoane PR, Farmer SG. Pharmacology and structure: activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Can J Physiol Pharmacol. 1995;73:805-811.
210. Sawutz DG, Salvino JM, Dolle RE, et al. The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist. Proc Natl Acad Sci U S A. 1994;91:4693-4697.
211. Sawutz DG, Salvino JM, Seoane PR, et al. Synthesis, characterization, and conformational analysis of the D/L-Tic7 stereoisomers of the bradykinin receptor antagonist D-Arg0[Hyp3,Thi5,D-Tic7,Oic8]bradykinin. Biochemistry. 1994;33:2373-2379.
212. Hopkins PC, Crowther DC, Carrell RW, Stone SR. Development of a novel recombinant serpin with potential antithrombotic properties. J Biol Chem. 1995;270:11866-11871.
213. Levy NJ, Ramesh N, Cicardi M, Harrison RA, Davis AE III. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1990;87:265-268.
214. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-217.
215. Frangi D, Cicardi M, Sica A, Colotta F, Agostoni A, Davis AE III. Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J Clin Invest. 1991;88:755-759.
216. Siddique Z, McPhaden AR, Lappin DF, Whaley K. An RNA splice site mutation in the C1-inhibitor gene causes type I hereditary angio-oedema. Hum Genet. 1991;88:231-232.
217. Siddique Z, McPhaden AR, McCluskey D, Whaley K. A single base deletion from the C1-inhibitor gene causes type I hereditary angio-oedema. Hum Hered. 1992;42:231-234.
218. Frangi D, Aulak KS, Cicardi M, Harrison RA, Davis AE III. A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444 →Leu). FEBS Lett. 1992;301:34-36.
219. Aulak KS, Eldering E, Hack CE, et al. A hinge region mutation in C1-inhibitor (Ala436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem. 1993;268:18088-18094.
220. Ocejo-Vinyals JG, Leyva-Cobian F, Fernandez-Luna JL. A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema. Mol Med. 1995;1:700-705.
221. Skriver K, Radziejewska E, Silbermann JA, Donaldson VH, Bock SC. CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem. 1989;264:3066-3071.
222. Aulak KS, Harrison RS. Rapid and sensitive techniques for identification and analysis of "reactive-centre" mutants of C1-inhibitor proteins contained in type II hereditary angio-oedema plasmas. Biochem J. 1990;271:565-569.
223. Siddique Z, McPhaden AR, Whaley K. Characterisation of nucleotide sequence variants and disease-specific mutations involving the 3′ end of the C1-inhibitor gene in hereditary angio-oedema. Hum Hered. 1995;45:98-102.
224. Ishii N, Ono H, Kawaguchi H, Nakajima H. Hereditary angioedema caused by a point mutation of exon 7 in the C1 inhibitor gene. Br J Dermatol. 1996;134:731-733.
225. Ono H, Kawaguchi H, Ishii N, Nakajima H. A point mutation in exon 7 of the C1-inhibitor gene causing type I hereditary angioedema. Hum Genet. 1996;98:452-453.
226. Bissler JJ, Donaldson VH, Davis AE III. Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Hum Genet. 1994;93:265-269.
227. Eldering E, Verpy E, Roem D, Meo T, Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem. 1995;270:2579-2587.
228. Ernst SC, Circolo A, Davis AE III, Gheesling-Mullis K, Fliesler M, Strunk RC. Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. J Immunol. 1996;157:405-410.
229. Bissler JJ, Meng QS, Emery T. C1 inhibitor gene sequence facilitates frameshift mutations. Mol Med. 1998;4:795-806.
230. Freiberger T, Kolarova L, Mejstrik P, Vyskocilova M, Kuklinek P, Litzman J. Five novel mutations in the C1 inhibitor gene (C1NH) leading to a premature stop codon in patients with type I hereditary angioedema. Hum Mutat. 2002;19:461.
231. Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians. 1997;109:164-173.
232. Tosi M. Molecular genetics of C1 inhibitor [published correction appears in Immunobiology. 1999;200:166]. Immunobiology. 1998;199:358-365.
233. Bowen B, Hawk JJ, Sibunka S, Hovick S, Weiler JM. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol. 2001;98:157-163.
234. Kalmar L, Bors A, Farkas H, et al. Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat. 2003;22:498.
235. Sekijima Y, Hashimoto T, Kawachi Y, Koshihara H, Otsuka F, Ikeda S. A novel RNA splice site mutation in the C1 inhibitor gene of a patient with type I hereditary angioedema. Intern Med. 2004;43:253-255.
236. Wisnieski JJ, Knauss TC, Yike I, Dearborn DG, Narvy RL, Naff GB. Unique C1 inhibitor dysfunction in a kindred without angioedema, I: a mutant C1 DMH that inhibits C1-s but not C1-r. J Immunol. 1994;152:3199-3209.
237. Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab. 1979;49:719-725.
238. Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen: levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb Haemost. 1985;54:454-459.
239. Brasher GW. C1q levels in hereditary angioedema. J Allergy Clin Immunol. 1977;59:263-265.
240. Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol. 2004;57:213-214.
241. Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy. 1989;63:301-305.
242. Verpy E, Biasotto M, Meo T, Tosi M. Efficient detection of point mutations on color-coded strands of target DNA. Proc Natl Acad Sci U S A. 1994;91:1873-1877.
243. Pappalardo E, Zingale LC, Cicardi M. C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J Allergy Clin Immunol. 2004;114:638-644.
244. Duponchel C, Di Rocco C, Cicardi M, Tosi M. Rapid detection by fluorescent multiplex PCR of exon deletions and duplications in the C1 inhibitor gene of hereditary angioedema patients. Hum Mutat. 2001;17:61-70.
245. Verpy E, Couture-Tosi E, Tosi M. C1 inhibitor mutations which affect intracellular transport and secretion in type I hereditary angioedema. Behring Inst Mitt. 1993;93:120-124.
246. Germain DP, Puech JP, Caillaud C, Kahn A, Poenaru L. Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease. Am J Hum Genet. 1998;63:415-427.
247. Saugier-Veber P, Martin C, Le Meur N, et al. Identification of novel L1CAM mutations using fluorescence-assisted mismatch analysis. Hum Mutat. 1998;12:259-266.
248. Moyret C, Theillet C, Puig PL, Moles JP, Thomas G, Hamelin R. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. Oncogene. 1994;9:1739-1743.
249. Dozy AM, Kan YW. Characterization of beta-thalassemia mutations by denaturing gradient gel electrophoresis: patterns in the Mediterranean mutations. Clin Genet. 1994;45:221-227.
250. Esteban-Cardenosa E, Duran M, Infante M, Velasco E, Miner C. High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis. Clin Chem. 2004 Feb; 50:313-320. Epub 2003 Dec 18.
251. Nataraj AJ, Olivos-Glander I, Kusukawa N, Highsmith WE Jr. Singlestrand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis. 1999;20:1177-1185.